Seamus Fernandez

Serge Belanger

Uy Ear

Douglas Tsao

Kambiz Yazdi

Vikram Purohit

Tyler Van Buren

Andrew Tsai

Ikenna Onwe

Judah Frommer

Richard Law

- Arcutis Biotherapeutics' lead product, **ZORYVE**, a topical PDE4 inhibitor, is approved for **four different diseases** and has been on the market for about **three years**, with **80% of commercial lives having access**.  **[1787306_tx_377390_0]** **[1787306_tx_377390_2]** 
- The company recently launched **ZORYVE Foam 0.3% for scalp and body psoriasis in June** and anticipates an expansion of the atopic dermatitis label in **October**.  **[1787306_tx_377390_0]** **[1787306_tx_377390_3]** 
- Arcutis reported **Q2 sales up 28% versus Q1** and expects **Q3 net sales to be higher than Q2**, with a projected return to strong growth in Q4.  **[1787306_tx_377390_2]** **[1787306_tx_377390_3]** 
- The company maintains its guidance to be **cash flow positive in 2026**, with ZORYVE's growth expected to fuel future lifecycle management and pipeline investments.  **[1787306_tx_377390_6]** 
- Beyond ZORYVE, the pipeline includes **ARQ-234**, a novel checkpoint agonist biologic for atopic dermatitis, which recently opened its IND.  **[1787306_tx_377390_0]**

Arcutis Biotherapeutics Discusses ZORYVE Performance and 2026 Cash Flow Positive Outlook

Arcutis Biotherapeutics (ARQT)